GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovation Pharmaceuticals Inc (OTCPK:IPIX) » Definitions » Cyclically Adjusted Book per Share

Innovation Pharmaceuticals (Innovation Pharmaceuticals) Cyclically Adjusted Book per Share : $0.01 (As of Sep. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Innovation Pharmaceuticals Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Innovation Pharmaceuticals's adjusted book value per share for the three months ended in Sep. 2023 was $0.002. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.01 for the trailing ten years ended in Sep. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Innovation Pharmaceuticals was 20.60% per year. The lowest was 20.60% per year. And the median was 20.60% per year.

As of today (2024-06-03), Innovation Pharmaceuticals's current stock price is $0.0015. Innovation Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 was $0.01. Innovation Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 0.15.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Innovation Pharmaceuticals was 1.60. The lowest was 0.00. And the median was 0.00.


Innovation Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

The historical data trend for Innovation Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovation Pharmaceuticals Cyclically Adjusted Book per Share Chart

Innovation Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 -0.02 -0.01 - 0.01

Innovation Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.01 0.01 0.01 0.01

Competitive Comparison of Innovation Pharmaceuticals's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Innovation Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovation Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovation Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Innovation Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Innovation Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Innovation Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Sep. 2023 was:

Adj_Book= Book Value per Share /CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=0.002/129.8595*129.8595
=0.002

Current CPI (Sep. 2023) = 129.8595.

Innovation Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201312 0.012 98.326 0.016
201403 0.009 99.695 0.012
201406 0.011 100.560 0.014
201409 0.040 100.428 0.052
201412 0.061 99.070 0.080
201503 0.083 99.621 0.108
201506 0.060 100.684 0.077
201509 0.051 100.392 0.066
201512 0.036 99.792 0.047
201603 0.024 100.470 0.031
201606 0.024 101.688 0.031
201609 0.017 101.861 0.022
201612 0.001 101.863 0.001
201703 0.009 102.862 0.011
201706 -0.011 103.349 -0.014
201709 -0.023 104.136 -0.029
201712 -0.020 104.011 -0.025
201803 -0.025 105.290 -0.031
201806 -0.013 106.317 -0.016
201809 -0.024 106.507 -0.029
201812 -0.024 105.998 -0.029
201903 -0.023 107.251 -0.028
201906 -0.020 108.070 -0.024
201909 -0.021 108.329 -0.025
201912 -0.026 108.420 -0.031
202003 -0.017 108.902 -0.020
202006 0.004 108.767 0.005
202009 0.013 109.815 0.015
202012 0.009 109.897 0.011
202103 0.024 111.754 0.028
202106 0.017 114.631 0.019
202109 0.018 115.734 0.020
202112 0.015 117.630 0.017
202203 0.012 121.301 0.013
202206 0.009 125.017 0.009
202209 0.007 125.227 0.007
202212 0.006 125.222 0.006
202303 0.005 127.348 0.005
202306 0.004 128.729 0.004
202309 0.002 129.860 0.002

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Innovation Pharmaceuticals  (OTCPK:IPIX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Innovation Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.0015/0.01
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Innovation Pharmaceuticals was 1.60. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Innovation Pharmaceuticals Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Innovation Pharmaceuticals's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovation Pharmaceuticals (Innovation Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
301 Edgewater Place, Suite 100, Wakefield, MA, USA, 01880
Innovation Pharmaceuticals Inc is a clinical-stage pharmaceutical company in the United States. It is engaged in developing therapies with oncology, dermatology, and antimicrobial applications. Its clinical trials focus on evaluating its drug candidates, including Kevetrin for the treatment of cancers; Brilacidin, a potential therapeutic for the treatment of the novel coronavirus. The company focuses on developing small molecule therapies to treat diseases in the areas of cancer, antibiotics, and inflammatory disease.
Executives
Arthur Peter Bertolino officer: Pres. & Chief Medical Officer C/O INNOVATION PHARMACEUTICALS INC., 100 CUMMINGS CENTER, SUITE 151-B, BEVERLY MA 01915
Jane A. Harness officer: Vice President 100 CUMMINGS CENTER, SUITE 151-B, BEVERLY MA 01915
Mark Robert Tobin director C/O LIGHTBRIDGE CORPORATION, 11710 PLAZA AMERICA DRIVE, SUITE 2000, RESTON VA 20190
Zorik Spektor director 17615 FIELDBROOK CIRCLE E, BOCA RATON FL 33496
Barry A Schechter director 7814 TENNYSON CT., BOCA RATON FL 33433
Leo Ehrlich director, 10 percent owner, officer: Chief Financial Officer C/O INNOVATION PHARMACEUTICALS INC., 301 EDGEWATER PLACE - SUITE 100, WAKEFIELD MA 01880
Krishna Menon director, 10 percent owner, officer: President-Chief Scient.Officer 10 BRIDLE WAY, NORTH READING MA 01864
George W. Evans director, officer: Chief Executive Officer 17 IRVING PLACE, PELHAM NY 10803

Innovation Pharmaceuticals (Innovation Pharmaceuticals) Headlines

From GuruFocus